Non-alcoholic fatty liver disease: the mist gradually clears

Area of Science:

• Hepatology
• Metabolic Diseases
• Gastroenterology

Background:

• Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disorder globally, affecting up to one-third of the population.
• NAFLD is strongly associated with metabolic syndrome components, including obesity and type 2 diabetes.
• The disease spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC).

Purpose of the Study:

• To provide a comprehensive overview of the current understanding of NAFLD.
• To discuss the association of NAFLD with metabolic syndrome and cardiovascular disease.
• To highlight diagnostic challenges and emerging therapeutic strategies for NAFLD.

Main Methods:

• Literature review of epidemiological, etiological, and clinical data on NAFLD.
• Analysis of the role of dietary and genetic factors in NAFLD pathogenesis.
• Examination of current diagnostic methods, including liver biopsy and emerging non-invasive techniques.

Main Results:

• NAFLD is a significant public health issue with increasing prevalence and potential for severe liver complications.
• Metabolic syndrome, obesity, and diabetes are key risk factors for NAFLD development and progression.
• Cardiovascular disease is a recognized comorbidity associated with NAFLD.
• Diagnosis often relies on exclusion, with liver biopsy remaining the gold standard for staging, though non-invasive methods are advancing.

Conclusions:

• NAFLD is a complex condition requiring a multi-faceted approach to management.
• Current therapeutic strategies focus on lifestyle modifications and managing associated metabolic conditions.
• Further research into novel therapeutic targets and non-invasive diagnostic tools is crucial for improving patient outcomes.